menu
    • menu
    [{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"V-Bio Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"CDK4\/CDK6","graph1":"Oncology","graph2":"Discovery","graph3":"Sibylla Biotech","amount2":0.02,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Sibylla Biotech \/ V-Bio Ventures","highestDevelopmentStatusID":"2","companyTruncated":"Sibylla Biotech \/ V-Bio Ventures"},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Neurology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Neurology","graph2":"Discovery Platform","graph3":"Sibylla Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"","sponsorNew":"Sibylla Biotech \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Sibylla Biotech \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Sibylla Biotech","sponsor":"University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Discovery","graph3":"Sibylla Biotech","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Sibylla Biotech \/ University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"2","companyTruncated":"Sibylla Biotech \/ University of Texas MD Anderson Cancer Center"}]

    Find Clinical Drug Pipeline Developments & Deals by Sibylla Biotech

    Menu

    Sibylla Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Sibylla Biotech

                            Italy arrow
                            Compamed
                            Not Confirmed

                            Sibylla Biotech

                            Italy arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sibylla Biotech and MD Anderson Collaborate on Small-Molecule Protein Degraders

                            Details : The collaboration aims to discover and develop novel small-molecule cancer therapies, Folding Interfering Degraders, which disrupt the proper folding of target proteins and lead to degradation.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 12, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : University of Texas MD Anderson Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sibylla Biotech

                            Italy arrow
                            Compamed
                            Not Confirmed

                            Sibylla Biotech

                            Italy arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Study Phase : Discovery Platform

                            Sponsor : Ono Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Sibylla Biotech Enters Strategic Collaboration with Ono for CNS Disorders

                            Details : Ono Pharmaceutical collaborates with Sibylla to use PPI-FIT technology for developing candidates for CNS disorders.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 14, 2024

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Neurology

                            Highest Development Status : Discovery Platform

                            Sponsor : Ono Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Sibylla Biotech

                            Italy arrow
                            Compamed
                            Not Confirmed

                            Sibylla Biotech

                            Italy arrow
                            Compamed
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery

                            Sponsor : V-Bio Ventures

                            Deal Size : $22.3 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Sibylla Biotech Raises €23 Million Series A to Advance Protein Degradation by Folding Interference Pipeline ...

                            Details : The proceeds of the Series A will allow the company to build out its pipeline of therapeutics by exploiting the protein folding simulation platform, as well as to further expand the potentiality of its technology.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 04, 2022

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery

                            Sponsor : V-Bio Ventures

                            Deal Size : $22.3 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth